Preventing lung pathology and mortality in rabbit Staphylococcus aureus pneumonia models with cytotoxin-neutralizing

Lukas Stulik1, Harald Rouha2, Delphine Labrousse3

  • 1Arsanis Biosciences, Vienna, Austria. lukas.stulik@arsanis.com.

Scientific Reports
|March 31, 2019
PubMed

Insights

ASN100, a combination of two monoclonal antibodies, effectively neutralizes Staphylococcus aureus cytotoxins. This treatment significantly improves survival and reduces lung damage in pneumonia models, offering a promising therapeutic strategy.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Pulmonology

Background:

  • Staphylococcus aureus pneumonia presents high mortality, independent of antibiotic resistance.
  • Both MRSA and MSSA strains produce cytotoxins like alpha-hemolysin (Hla) and leukocidins, crucial for immune evasion.
  • Previous studies indicate neutralizing these toxins can improve survival in pneumonia models.

Purpose of the Study:

  • To evaluate the protective efficacy of ASN100, a dual monoclonal antibody therapy, against S. aureus pneumonia in rabbit models.
  • To investigate the mechanism of ASN100's protection by assessing its impact on lung pathology and bacterial burden.
  • To determine the pharmacokinetic profile of ASN100 in lung tissue.

Main Methods:

  • Prophylactic passive immunization with ASN100 in rabbit models of MRSA and MSSA pneumonia.
  • Assessment of survival rates, macroscopic and microscopic lung pathology, edema, and bacterial burden at 12 hours post-infection.
  • Pharmacokinetic analysis of ASN100 in bronchoalveolar-lavage fluid and serum.

Main Results:

  • ASN100 demonstrated dose-dependent increases in survival and provided full protection at 5 or 20 mg/kg against all tested S. aureus strains.
  • Treatment with ASN100 significantly reduced lung pathology, edema, and bacterial burden.
  • Efficient penetration of ASN100 into lung epithelial lining fluid was observed, with peak concentrations comparable to serum levels.

Conclusions:

  • ASN100 effectively neutralizes key S. aureus cytotoxins in the lung.
  • The antibody combination prevents damage to the mucosal barrier and innate immune cells, improving outcomes in pneumonia.
  • ASN100 represents a potential therapeutic strategy for S. aureus pneumonia by targeting virulence factors.

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.5K
The Fluid Mosaic Model01:34

The Fluid Mosaic Model

The fluid mosaic model was first proposed as a visual representation of research observations. The model comprises the composition and dynamics of membranes and serves as a foundation for future membrane-related studies. The model depicts the structure of the plasma membrane with a variety of components, which include phospholipids, proteins, and carbohydrates. These integral molecules are loosely bound, defining the cell’s border and providing fluidity for optimal function.
177.6K
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.1K
Models of Health Promotion and Illness Prevention II01:18

Models of Health Promotion and Illness Prevention II

The person's health status fluctuates continually, varying from being in good health to becoming ill and returning to being healthy. To understand the concept of illness prevention, there are two models. First, the health-illness continuum model is a graphic representation of an individual's wellness. It states that a person is considered healthy in the absence of physical disease and the presence of good emotional health.
The agent-host-environment model states that disease results...
2.1K
Fluid Mosaic Model01:19

Fluid Mosaic Model

Scientists identified the plasma membrane in the 1890s and its principal chemical components (lipids and proteins) by 1915. The model for plasma membrane structure, proposed in 1935 by Hugh Davson and James Danielli, was the first model to be widely accepted in the scientific community. The model was based on the plasma membrane's "railroad track" appearance in early electron micrographs. Davson and Danielli theorized that the plasma membrane's structure resembled a sandwich...
15.9K
Models of Health Promotion and Illness Prevention I01:25

Models of Health Promotion and Illness Prevention I

A model is a theoretical way to understand a concept or an idea. Models can overcome barriers to health regardless of diverse economic and cultural backgrounds. In addition, models make the task easier by providing different ways to approach complex issues. There are two major health promotion models: the health belief model and the health promotion model.
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
2.8K